An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
1 other identifier
observational
2,740
0 countries
N/A
Brief Summary
This is a prospective, observational, longitudinal, multicenter study of patients with newly diagnosed follicular Non Hodgkin's Lymphoma (NHL) designed to delineate differences in clinical outcome by comparing the effectiveness and safety of common treatment regimens.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2004
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2004
CompletedFirst Submitted
Initial submission to the registry
November 24, 2004
CompletedFirst Posted
Study publicly available on registry
November 25, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedMarch 23, 2017
March 1, 2017
10 years
November 24, 2004
March 21, 2017
Conditions
Keywords
Eligibility Criteria
Patients with follicular NHL will be recruited from participating managed care organizations, community physicians or practices, and academic centers throughout the United States.
You may qualify if:
- Signed Informed Consent Form (unless the Institutional Review Board \[IRB\] has granted a waiver of consent)
- Signed Authorization for the Use and Disclosure of Health Information document
- Age ≥18 years
- Histologic documentation of follicular NHL, according to Revised European-American Lymphoma (REAL) classification system, as assessed by the local pathologist and treating physician
- Initial diagnosis of follicular B-cell NHL within 6 months prior to enrollment
- Availability of cancer-specific historical data points in the patient's medical records
You may not qualify if:
- Other indolent or histologic NHL subtypes
- Diagnosis of lymphoma \> 6 months prior to enrollment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Genentech, Inc.lead
Related Publications (2)
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol. 2016 Mar;172(5):724-34. doi: 10.1111/bjh.13895. Epub 2016 Jan 5.
PMID: 26729445DERIVEDWagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, Friedberg JW, Bartlett NL. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015 Aug 13;126(7):851-7. doi: 10.1182/blood-2015-01-621375. Epub 2015 Jun 23.
PMID: 26105149DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Cinical Trials
Genentech, Inc.
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 24, 2004
First Posted
November 25, 2004
Study Start
March 1, 2004
Primary Completion
March 1, 2014
Study Completion
March 1, 2014
Last Updated
March 23, 2017
Record last verified: 2017-03